Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONCE

Spark Therapeutics (ONCE) Stock Price, News & Analysis

Spark Therapeutics logo

About Spark Therapeutics Stock (NASDAQ:ONCE)

Advanced Chart

Key Stats

Today's Range
$0.18
$0.18
50-Day Range
$110.05
$113.57
52-Week Range
$34.53
$114.20
Volume
N/A
Average Volume
891,560 shs
Market Capitalization
$6.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCE Stock News Headlines

The world’s first multi- trillion-dollar robotics industry …
Robots are standing on the edge of history. No one would know this better than Nvidia's Jensen Huang. In Las Vegas, the CEO of the world's most valuable company did more than just talk. He laid out their vision for building the world's first trillion-dollar robot. Kickstarting a multi-trillion-dollar robotics industry.
See More Headlines

ONCE Stock Analysis - Frequently Asked Questions

Spark Therapeutics Inc (NASDAQ:ONCE) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative trailing twelve-month return on equity of 59.10%.

Spark Therapeutics (ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spark Therapeutics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Meta Platforms (META), Alibaba Group (BABA), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/07/2018
Today
5/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCE
Fax
N/A
Employees
368
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,820,000.00
Net Margins
-358.41%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$64.72 million
Price / Cash Flow
N/A
Book Value
$13.15 per share
Price / Book
0.01

Miscellaneous

Free Float
N/A
Market Cap
$6.94 million
Optionable
No Data
Beta
2.05
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ONCE) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners